KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer

MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer

Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy

Ovarian highlights from ESMO 2019

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Real-world use of carfilzomib in relapsed multiple myeloma patients with pre-existing cardiovascular comorbidities

Adding daratumumab to existing multiple myeloma regimen of lenalidomide, bortezomib and dexamethasone

Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma

What is the role of autologous stem cell transplant in multiple myeloma?

Practical considerations for introducing biosimilars

Successful implementation of biosimilars through effective communication

How real-world data generation can assist biosimilar implementation